Loading
A phase 1/2 trial of LUM015 in colorectal cancer, pancreatic ductal adenocarcinoma, oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by Lumicell, Inc., now recruiting.
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers is a phase 1/2 interventional study registered as NCT02584244 by Lumicell, Inc., with 66 participants planned, started 2016-08-04 and due to reach its primary completion in 2026-12. Interventions recorded: LUM015 and LUM 2.6 Imaging Device.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/